Cancer Comprehensive Panel NGS Genetic Test – AED 4400.0
The Cancer Comprehensive Panel NGS Genetic DNA Test offered by DNA Labs UAE is a diagnostic test that analyzes a patient’s DNA to identify genetic mutations associated with cancer. This test is performed using next-generation sequencing (NGS) technology to detect changes in a large number of genes that may be involved in the development and progression of cancer.
Test Details
The Cancer Comprehensive Panel NGS Genetic DNA Test is typically conducted on a tumor biopsy sample or a blood sample from a patient with cancer. It can detect various genetic alterations, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and gene fusions.
The results of this test provide valuable information to oncologists and other healthcare providers, enabling them to determine the most suitable course of treatment for the patient. Additionally, the test helps identify patients who may be eligible for targeted therapies or clinical trials based on their specific genetic profile.
Overall, the Cancer Comprehensive Panel NGS Genetic DNA Test is a powerful tool for personalized medicine in the field of oncology. It allows healthcare providers to tailor treatment plans to individual patients based on their unique genetic makeup.
Test Components and Price
The Cancer Comprehensive Panel NGS Genetic DNA Test costs AED 4400.0. The test requires a blood sample or extracted DNA. Alternatively, a single drop of blood can be collected on an FTA card. The report is typically delivered within 3 to 4 weeks using NGS technology.
Pre-Test Information
Prior to undergoing the Cancer Comprehensive Panel NGS Genetic DNA Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session is conducted to draw a pedigree chart of family members affected with specific genes associated with cancer. Some of the genes included in the panel are ABRAXAS1, ACVRL1, AKT1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DDX41, DICER1, DIS3L2, EGFR, EPCAM, ETV6, EXT1, EXT2, FANCC, FH, FLCN, GALNT12, GATA2, GPC3, GREM1, HNF1A, HNF1B, HOXB13, HRAS, KIF1B, KIT, MAX, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS1, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL, REST, RET, RNF43, RPS20, RUNX1, SAMD9L, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA2, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERT, TGFBR2, TMEM127, TP53, TRIP13, TSC1, TSC2, VHL, WRN, WT1, XRCC2, and XRCC3.
Conclusion
The Cancer Comprehensive Panel NGS Genetic DNA Test provided by DNA Labs UAE is an essential tool for diagnosing and treating cancer. By analyzing a patient’s DNA, this test helps identify genetic mutations associated with cancer and provides valuable information for personalized treatment plans. The test’s ability to detect a wide range of genetic alterations makes it a powerful tool in the field of oncology, enabling healthcare providers to offer targeted therapies and identify potential candidates for clinical trials.
Test Name | Cancer comprehensive panel NGS Genetic DNA Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Cancer |
Doctor | Oncologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for Cancer comprehensive panel NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ABRAXAS1, ACVRL1, AKT1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DDX41, DICER1, DIS3L2, EGFR, EPCAM, ETV6, EXT1, EXT2, FANCC, FH, FLCN, GALNT12, GATA2, GPC3, GREM1, HNF1A, HNF1B, HOXB13, HRAS, KIF1B, KIT, MAX, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS1, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL, REST, RET, RNF43, RPS20, RUNX1, SAMD9L, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA2, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERT, TGFBR2, TMEM127, TP53, TRIP13, TSC1, TSC2, VHL, WRN, WT1, XRCC2, XRCC3 |
Test Details |
The Cancer Comprehensive Panel NGS Genetic DNA Test is a diagnostic test that analyzes a patient’s DNA to identify genetic mutations associated with cancer. This test uses next-generation sequencing (NGS) technology to detect changes in a large number of genes that may be involved in the development and progression of cancer. The test is typically performed on a tumor biopsy sample or a blood sample from a patient with cancer. It can detect a wide range of genetic alterations, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and gene fusions. The results of the Cancer Comprehensive Panel NGS Genetic DNA Test can provide valuable information to oncologists and other healthcare providers, helping them to determine the best course of treatment for the patient. The test can also help identify patients who may be eligible for targeted therapies or clinical trials based on their specific genetic profile. Overall, the Cancer Comprehensive Panel NGS Genetic DNA Test is a powerful tool for personalized medicine in the field of oncology, allowing healthcare providers to tailor treatment plans to individual patients based on their unique genetic makeup. |